Results 61 to 70 of about 4,653 (155)

Revisiting the Ethics of Urate‐Lowering Therapy Clinical Trials for Gout Management

Arthritis &Rheumatology, Volume 78, Issue 8, Page 1632-1635, August 2026.
Lisa K. Stamp, Dien Ho, Nicola Dalbeth
wiley   +1 more source

Febuxostat.

Australian prescriber, 2015
  +8 more sources

Comparative efficacy and safety of febuxostat and allopurinol in chronic kidney disease stage 3–5 patients with asymptomatic hyperuricemia: a network meta-analysis

Renal Failure
Objective This study evaluates and compares the effectiveness and safety of febuxostat and allopurinol in chronic kidney disease (CKD) stages 3–5 patients with asymptomatic hyperuricemia using a network meta-analysis.Methods A systematic review and ...
Jiaojiao Chen, Yanyun Zhang, Yinglin Wang, Lu Chen   +3 more
doaj   +1 more source

Xanthine oxidoreductase inhibition ameliorates high glucose-induced glomerular endothelial injury by activating AMPK through the purine salvage pathway

Scientific Reports
Xanthine oxidoreductase (XOR) contributes to reactive oxygen species production. We investigated the cytoprotective mechanisms of XOR inhibition against high glucose (HG)-induced glomerular endothelial injury, which involves activation of the AMP ...
Keum-Jin Yang, Hwajin Park, Yoon-Kyung Chang, Cheol Whee Park, Suk Young Kim, Yu Ah Hong   +5 more
doaj   +1 more source

Febuxostat efficiently reduces the progression of chronic kidney disease in asymptomatic hyperuricemia: an interventional study

The Egyptian Journal of Internal Medicine
Background Therapeutic approaches for addressing asymptomatic chronic kidney disease (CKD) with renal impairment requires careful consideration, as there is a lack of substantial evidence endorsing specific medications.
Showkat Azad, Pradip Kumar Dutta, Md Nurul Huda, Mohammad Abdul Kader, Biplob Kumar Barua, Mohammad Shawkat Ali, Maria Mehjabin Akhi, Mishu Rahman, Jannatul Efte Ekra, Md. Sujan Islam, Sadia Afrin, Mohammed Mehadi Hassan Chowdhury, Subodh Kumar Sarkar, Ashekul Islam   +13 more
doaj   +1 more source

Efficacy and safety of febuxostat in elderly female patients

Clinical Interventions in Aging, 2014
Tomohiro Mizuno,1,2 Takahiro Hayashi,3 Sayo Hikosaka,1 Yuka Shimabukuro,1 Maho Murase,1 Kazuo Takahashi,2 Hiroki Hayashi,2 Yukio Yuzawa,2 Tadashi Nagamatsu,1 Shigeki Yamada3 1Department of Analytical Pharmacology, Graduate School of Pharmacy, Meijo ...
Mizuno T, Hayashi T, Hikosaka S, Shimabukuro Y, Murase M, Takahashi K, Hayashi H, Yuzawa Y, Nagamatsu T, Yamada S   +9 more
doaj  

Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta‐analysis

Clinical and Translational Science
The cardiovascular (CV) safety of febuxostat compared to allopurinol for the treatment of hyperuricemia among Asian patients is uncertain. In this study, we conducted a systematic review and meta‐analysis to compare the CV safety profiles of febuxostat ...
Jian‐hao Deng, Peng‐hui Lai, Li‐shan Xie, Shu‐sheng Qiu, De‐sheng Qiu, Jia‐xing Zhang   +5 more
doaj   +1 more source

Comparative assessment of the effects of dotinurad and febuxostat on the renal function in chronic kidney disease patients with hyperuricemia

Scientific Reports
Although hyperuricemia is associated with chronic kidney disease (CKD), the impact of uric acid (UA)-lowering drugs on CKD has been controversial.
Tomoaki Takata, Sosuke Taniguchi, Yukari Mae, Kana Kageyama, Yudai Fujino, Takuji Iyama, Katsuya Hikita, Takaaki Sugihara, Hajime Isomoto   +8 more
doaj   +1 more source

Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat

ClinicoEconomics and Outcomes Research, 2017
Richard Sheer,1 Kyle D Null,2 Keith A Szymanski,2 Lavanya Sudharshan,1 Jennifer Banovic,2 Margaret K Pasquale1 1Comprehensive Health Insights, Inc., Louisville, KY, 2Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL, USA Purpose: Clinical guidelines ...
Sheer R, Null KD, Szymanski KA, Sudharshan L, Banovic J, Pasquale MK   +5 more
doaj  

Febuxostat in the management of hyperuricemia and chronic gout: a review

Therapeutics and Clinical Risk Management, 2008
Miao Hu, Brian TomlinsonDivision of Clinical Pharmacology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, ChinaAbstract: Febuxostat is a novel, potent, non ...
Miao Hu, Brian Tomlinson
doaj